180 Life Sciences appoints Blair Jordan as independent director; compensation includes deferred cash fees

FORUM MARKETS Inc

Blair Jordan appointed as Class II director effective Feb 28, 2024; serves as Lead Independent Director and Chair of Strategy & Alternatives Committee.
Annual cash compensation: $40K retainer + $10K committee chair + $15K lead director; initial payment $7,500.
Half of cash compensation accrued until company raises $1M aggregate from any source.
Jordan is independent under Nasdaq rules; serves on Audit, Compensation, Nominating and Governance, and Risk committees.
Jordan previously served as interim CEO/CFO of Ascent Industries, which obtained creditor protection under CCAA.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Blair Jordan

Director

FRMM · FORUM MARKETS Inc

Effective: 2024-02-28
Filed: February 29, 2024, 6:59 PM ET

February 28, 2024, the Board of Directors of 180 Life Sciences Corp. (the “ Company ”, “ we ” and “ us ”), appointed Blair Jordan as a member of the Board of Directors (“ Board ”), to fill one of the vacancies on the Board

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Blair Jordan was appointed as Director at FORUM MARKETS Inc.

Action: appointed
Role: Director

Exact text from the filing

February 28, 2024, the Board of Directors of 180 Life Sciences Corp. (the “ Company ”, “ we ” and “ us ”), appointed Blair Jordan as a member of the Board of Directors (“ Board ”), to fill one of the vacancies on the Board

View on SEC.gov

FORUM MARKETS Inc filing history →

Source: SEC EDGAR

accession 0001213900-24-018231

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.